Fulgent Genetics

General Information

We are a rapidly growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. We have developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows us to offer a broad and flexible test menu while maintaining accessible pricing, high accuracy and competitive turnaround times. We believe our current test menu offers more genes for testing than our competitors in today’s market, which enables us to provide expansive options for test customization and clinically actionable results. Our current test menu includes more than 18,000 single-gene tests and more than 200 pre-established, multi-gene, disease-specific panels that collectively test for more than 7,500 genetic conditions, including various cancers, cardiovascular diseases and neurological disorders.

Employees: 55
Founded: 2011
Contact Information
Address 4978 Santa Anita Avenue, Temple City, CA 91780, US
Phone Number (626) 350-0537
Web Address http://www.fulgentgenetics.com
View Prospectus: Fulgent Genetics
Financial Information
Market Cap $153.5mil
Revenues $13.22 mil (last 12 months)
Net Income $-13.23 mil (last 12 months)
IPO Profile
Symbol FLGT
Exchange NASDAQ
Shares (millions): 4.2
Price range $9.00 - $9.00
Est. $ Volume $37.8 mil
Manager / Joint Managers Credit Suisse/ Piper Jaffray
CO-Managers Raymond James/ BTIG
Expected To Trade: 9/29/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change